In vivo delivery aspects of miRNA, shRNA and siRNA
- PMID: 23176057
- DOI: 10.1615/critrevtherdrugcarriersyst.v29.i6.20
In vivo delivery aspects of miRNA, shRNA and siRNA
Abstract
RNA interference (RNAi) is a wondrous phenomenon that silences the expression of targeted genes via distinct messenger RNA degradation pathways. It has the potential as a therapeutic agent for variety of diseases, including viral infections, cancer, and immune diseases. RNAi mainly conducts gene regulation by 3 ways: microRNA, short hairpin RNA, and small interfering RNA. However, in vivo delivery of RNAi therapeutics is restricted because of charge density, molecular weight, and instability in the presence of nucleases. Furthermore, intracellular accumulation and endosomal escape have remained significant barriers in the delivery of these macromolecules. Many viral and nonviral delivery vectors have been thoroughly investigated to overcome these barriers. Researchers have found applications for RNAi in a variety of diseases and, hence, various delivery systems have been explored to satisfy the need. Both local and systemic strategies have been utilized to elicit RNAi's effect and each carries its own therapeutic implications with varying margins of safety. This review is an effort to describe the types of RNAi and their application in a variety of diseases using both local and systemic delivery approaches. It is sure that advancement in this direction will evolve a new landscape for treating a range of diseases.
Similar articles
-
Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.Pharm Res. 2011 Dec;28(12):2996-3015. doi: 10.1007/s11095-011-0608-1. Epub 2011 Oct 28. Pharm Res. 2011. PMID: 22033880 Review.
-
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21. Adv Drug Deliv Rev. 2007. PMID: 17481774 Review.
-
Are Viral Vectors Any Good for RNAi Antiviral Therapy?Viruses. 2020 Oct 20;12(10):1189. doi: 10.3390/v12101189. Viruses. 2020. PMID: 33092124 Free PMC article.
-
In vivo application of RNA interference: from functional genomics to therapeutics.Adv Genet. 2005;54:117-42. doi: 10.1016/S0065-2660(05)54006-9. Adv Genet. 2005. PMID: 16096010 Free PMC article. Review.
-
RNAi in clinical studies.Curr Med Chem. 2013;20(14):1801-16. doi: 10.2174/09298673113209990118. Curr Med Chem. 2013. PMID: 23432579 Review.
Cited by
-
A concise review on miRNAs as regulators of colon cancer stem cells and associated signalling pathways.Clin Transl Oncol. 2023 Dec;25(12):3345-3356. doi: 10.1007/s12094-023-03200-x. Epub 2023 Apr 22. Clin Transl Oncol. 2023. PMID: 37086351 Review.
-
Decrease of murine cytomegalovirus-induced retinitis by intravenous delivery of immediate early protein-3-specific siRNA.Invest Ophthalmol Vis Sci. 2014 Jun 6;55(7):4151-7. doi: 10.1167/iovs.14-14375. Invest Ophthalmol Vis Sci. 2014. PMID: 24906861 Free PMC article.
-
Live-Attenuated Bacterial Vectors: Tools for Vaccine and Therapeutic Agent Delivery.Vaccines (Basel). 2015 Nov 10;3(4):940-72. doi: 10.3390/vaccines3040940. Vaccines (Basel). 2015. PMID: 26569321 Free PMC article. Review.
-
Is miR-21 A Therapeutic Target in Cardiovascular Disease?Int J Drug Discov Pharm. 2023 Apr;2(1):26-36. doi: 10.53941/ijddp.0201003. Epub 2023 Jan 11. Int J Drug Discov Pharm. 2023. PMID: 37799562 Free PMC article.
-
Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transition.Cancer Cell Int. 2015 Feb 25;15:24. doi: 10.1186/s12935-015-0174-4. eCollection 2015. Cancer Cell Int. 2015. PMID: 25792974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources